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Is attendant at delivery associated with the use of
interventions to prevent postpartum hemorrhage
Ndola Prata1*, Suzanne Bell2, Martine Holston3 and Mohammad A Quaiyum4
at home births? he case of BangladeshAbstract
Background: Hemorrhage is the leading cause of maternal mortality in Bangladesh, the majority of which is due to
postpartum hemorrhage (PPH), blood loss of 500 mL or more. Many deaths due to PPH occur at home where
approximately 77% of births take place. This paper aims to determine whether the attendant at home delivery
(i.e. traditional birth attendant (TBA) trained on PPH interventions, TBA not trained on interventions, or lay
attendant) is associated with the use of interventions to prevent PPH at home births.
Methods: Data come from operations research to determine the safety, feasibility, and acceptability of scaling-up
community-based provision of misoprostol and an absorbent delivery mat in rural Bangladesh. Analyses were done
using data from antenatal care (ANC) cards of women who delivered at home without a skilled attendant
(N = 66,489). Multivariate logistic regression was used to assess the likelihood of using the interventions.
Results: Overall, 67% of women who delivered at home without a skilled provider used misoprostol and the
delivery mat (the interventions). Women who delivered at home and had a trained TBA present had 2.72 (95%
confidence interval, 2.15-3.43) times the odds of using the interventions compared to those who had a lay person
present. With each additional ANC visit (maximum of 4) a woman attended, the odds of using the interventions
increased 2.76 times (95% confidence interval, 2.71-2.81). Other sociodemographic variables positively associated
with use of the interventions were age, secondary or higher education, and having had a previous birth.
Conclusion: Findings indicate that trained TBAs can have a significant impact on utilization of interventions to
prevent PPH in home births. ANC visits can be an important point of contact for knowledge transfer and message
reinforcement about PPH prevention.
Keywords: Bangladesh, Maternal mortality, Postpartum hemorrhage, Misoprostol, Delivery mat, Home delivery,
Traditional birth attendantBackground
It is estimated that postpartum hemorrhage (PPH) ac-
counts for 25% of global maternal death [1,2]. In low-
resource settings, the vast majority of women deliver at
home, unattended by a skilled provider and with inad-
equate resources should emergency obstetric care be
needed [1,3]. Contributing to the difficulty of addressing
the problem is the low predictive probability of PPH [4]
and the speed at which PPH kills; 88% of women are dead* Correspondence: ndola@berkeley.edu
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reproduction in any medium, provided the orwithin 4 hours of delivery [3]. The compounding effect of
the biological and contextual circumstances helps to ex-
plain why PPH continues to be the leading cause of mater-
nal death in low-resource settings despite concerted
efforts to address the problem.
In Bangladesh, the maternal mortality ratio is 194 per
100,000 live births [5]. Hemorrhage is the leading cause of
maternal mortality in Bangladesh, accounting for 31% of
total maternal deaths; postpartum hemorrhage (PPH) in
particular is largely responsible for these deaths [5]. Many
deaths due to PPH occur at home where approximately
77% of births take place [5]. Of the 2.4 million births that
take place at home annually, only 4.3% use a medicallyd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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[5]. Reducing the number of deaths attributable to PPH
will require community-based use of evidence-based tech-
nologies that can be used by low-level or lay birth atten-
dants [6].
Ideally a skilled provider would administer active man-
agement of the third stage of labor (AMTSL) immediately
following delivery, an intervention that can prevent more
than half of PPH cases [7]. With such a high proportion of
home births, nearly all of which have no skilled attendant
and no clear trend away from such practices, it is unrealistic
to rely exclusively on AMTSL administration by a skilled
provider as a means of preventing PPH. Bringing the most
effective component of AMTSL, the uterotonic drug [4], to
the community-level has the potential to prevent PPH at-
tributable death among the most vulnerable women.
Misoprostol is an affordable, thermostable uterotonic
that has been demonstrated to be safe and effective in the
prevention of PPH at the community-level [8-10]. Prophy-
lactic use of misoprostol at home births in comparison to
a placebo can reduce the risk of PPH by 24% to 47% [8,9].
Unlike oxytocin, the preferred uterotonic in the manage-
ment of PPH, it can be administered orally/sublingually
instead of parenteral. This allows low-level providers and
even the delivering woman herself to administer miso-
prostol; operations research has demonstrated the feasibil-
ity, safety, effectiveness, and acceptability of this approach
[11-17]. Based on a review of existing evidence, the WHO
added misoprostol to the Essential Medicines List for the
prevention of PPH in 2011 [18] and in its most recent
guidelines for PPH prevention and treatment, the WHO
recommends the use of misoprostol by community and
lay healthcare workers where skilled attendance and oxy-
tocin are not available [19].
Even with prophylactic use of misoprostol at home deliv-
eries, some women will experience PPH and need immedi-
ate transfer to a facility for further treatment. Identifying
PPH cases presents its own difficulties. When using visual
observation alone, amount of blood loss is often underesti-
mated, which can result in delayed referral and subsequent
fatality [20]. Using a measurement tool, like the “kanga” in
Tanzania, can allow whoever is present at a home delivery
to more accurately gauge blood loss and help ensure timely
transfer when necessary [21]. Use of misoprostol in con-
junction with a blood measurement tool provides a means
of preventing the leading cause of maternal mortality at the
community-level, helping to address the inequity of health-
care access in low-resource settings.
This paper aims to determine whether the attendant at
delivery (i.e. traditional birth attendant (TBA) trained on
PPH interventions, TBA not trained on interventions, or
lay attendant, which includes a family member or neigh-
bor) is associated with the use of interventions to prevent
PPH at home births.Methods
Intervention
Researchers conducted operations research to deter-
mine the safety, feasibility, and acceptability of scaling-
up community-based provision of misoprostol and an
absorbent delivery mat at home births in rural Bangladesh.
The study was implemented in the six northern-most
rural districts of Rangpur Division, Bangladesh. From July
2009 to January 2011, study personnel enrolled a total of
118,594 women, 77,337 of which delivered during the data
collection period. All women who enrolled were registered
antenatal care (ANC) clients of Rangpur Dinajpur Rural
Services (RDRS), Bangladesh, a local non-governmental
organization (NGO) that has been providing services to
the rural poor in the study area since 1972.
RDRS has 62 community health workers (CHWs) and
nearly 600 TBAs working in their reproductive health pro-
gram, which is based out of 203 ANC clinics throughout
the six study districts. TBAs are responsible for recruiting
and registering women in RDRS’ ANC program by going
door-to-door in their respective communities. They also
attend ANC at their affiliated clinic once a week and at-
tend home deliveries of RDRS registered women who re-
quest their services. CHWs lead the clinic-based ANC and
provide oversight of the TBAs who work in their upazilas
(sub-districts). Prior to the start of the study, RDRS was
providing clean delivery kits (CDKs) to women at a nom-
inal cost. CDKs contained a sterile razor blade, thread,
cotton gauze, a plastic sheet on which to deliver, and a bar
of soap. TBAs attending home deliveries used only visual
estimation to determine PPH cases and were instructed to
immediately transfer all suspected cases to a nearby
facility.
For the operations research, 600 μg of misoprostol
(three 200 μg tablets) and an absorbent delivery mat for
measurement of blood loss (developed by Dr. MA
Quaiyum and colleagues at the International Centre for
Diarrhoeal Disease Research, Bangladesh (icddr,b)) were
incorporated into the existing CDK [21]. RDRS did not
charge for these additional CDK components. CHWs con-
tinued to provide the CDKs to women through ANC at 32
weeks or beyond, and TBAs began distributing CDKs at
the time of delivery if women did not receive the CDK
through ANC. TBAs and CHWs received two days of
training on the new additions to the CDK. The training in-
cluded information on myriad aspects of misoprostol use
(function, dosage, timing of administration, side effects
and their management, etc.) and the absorbent delivery
mat. The training also covered information regarding the
identification of high-risk pregnancies, danger signs of
pregnancy, referral procedures, stages of labor, newborn
resuscitation, maternal infection, and general use of the
CDKs. Trainers particularly focused on PPH and other
pregnancy complications that require referral. Evidence
Table 1 Use of misoprostol and absorbent delivery mat
among women who delivered at home without a skilled
provider by sociodemographic and pregnancy
characteristics (N = 66,489)*
% that used interventions N
Total 67.4 64,413
Age
15-19 67.8 20,558
20-24 66.9 21,759
25-29 67.9 15,209
30-34 67.1 5,008
35-39 62.9 1,487
40-44 66.2 151
45-49 50.0 40
Education
None 63.0 12,380
Primary 64.4 19,104
Secondary 70.8 29,474
College 69.3 3,066
Gravidity
1 66.9 25,430
2+ 67.6 38,909
Number of ANC visits
Average 3.2
1 19.7 6,844
2 42.4 8,922
3 66.5 15,196
4 84.2 33,419
Attendant at delivery
Lay person 53.8 355
TBA 47.7 10,738
RDRS trained TBA 71.4 53,291
*N categories do not add up to 66,489 due to missing responses from
some women.
Prata et al. BMC Pregnancy and Childbirth 2014, 14:24 Page 3 of 6
http://www.biomedcentral.com/1471-2393/14/24from previous analyses indicate that TBAs learned and
retained key information about the new technologies
and utilized the tools correctly and to the satisfaction of
patients [22].
An information, education, and communication (IEC)
campaign accompanied the operations research. Women,
family members, and communities learned about the new
CDK through extensive IEC efforts outside of service de-
livery. Women received additional information about the
new CDK components from CHWs at clinic-based ANC.
In this analysis, we used program data to determine if,
among those who delivered at home without a skilled
provider, the use of the study interventions (misoprostol
and the absorbent delivery mat) is associated with the at-
tendant at delivery.
Analysis
Data analyzed are from ANC cards. All women enrolled
in the study received an ANC card that was filled out by
CHWs during ANC (N = 118,594) and then during a post-
delivery checkup for those who delivered during the study
period (N = 77,337). It contains information on basic
demographics, index pregnancy, obstetric history (if ap-
plicable), ANC information, enrollment status, whether or
not she received the CDK, and delivery information (i.e.
place of delivery, outcome, CDK use, attendant, referral,
etc.). All data collected on this card were entered into a
database using Epi Info™ version 3.5.1 [23] and analyzed
using STATA® version 11.0 [24].
All analyses were done with the subpopulation of
women who delivered at home during the study period
(N = 67,611) and who did not have a doctor or nurse
present (N = 66,489). Univariate and bivariate (Chi-square)
analyses were conducted. Using results from the bivariate
analyses, all covariates associated with the use of the study
interventions (dependent variable) at the p ≤ 0.20 level
were included in the multivariate model. Logistic regres-
sion with odds ratios and 95% confidence intervals was
then used to determine whether attendant at delivery had
a significant impact on the likelihood of use of the inter-
ventions. Observations with missing values for any of the
variables included in the logistic regression were dropped.
This resulted in a 4% reduction in the number of women
included in the final analysis.
Ethical approval for the operations research was provided
by the Committee for the Protection of Human Subjects at
the University of California, Berkeley (protocol #2008-8-24)
and by icddr,b’s research administration in Bangladesh. The
RDRS staff did not employ any coercive methods to collect
information from participating women and women were
free to not answer any questions without penalty or impact
on service delivery. The data collected were de-identified
and this secondary data analysis did not require additional
ethical approval or authorization.Results
Overall, 67% of women who delivered at home without a
skilled provider used misoprostol and the absorbent deliv-
ery mat (the interventions) to prevent PPH (Table 1).
Across most age categories, 60-70% of women used the in-
terventions, but only 50% of women ages 45–49 used the
interventions (Table 1). Similar proportions of women
used the interventions regardless of level of education and
gravidity (60-70%). Use of the interventions was positively
correlated with number of ANC visits, with women who
attended only one ANC visit being least likely to use the
interventions (20%) and women who attended four ANC
visits being most likely (84%) (Table 1). Percent of women
who used the interventions was highest among those who
had an RDRS trained TBA present (71%) compared to
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(54%) present (Table 1). Bivariate results revealed that all
covariates, which include attendant at delivery, age, educa-
tion, gravidity, and number of ANC visits, were signifi-
cantly associated with the use of study interventions at the
p ≤ 0.20 level (data not shown).
Based on the bivariate results, all covariates were in-
cluded in the multivariate model. Women who delivered
at home and had an RDRS trained TBA present had 2.72
times the odds of using the interventions compared to
those who had a lay person present (95% confidence inter-
val, 2.15-3.43) (Table 2). Compared to women ages 15–19,
women ages 20–24 and 25–29 were not more likely to use
the interventions, nor were the eldest women surveyed
(ages 45–49). However, women ages 30–34, 35–39, and
40–44 were increasingly more likely to use the interven-
tions, and these findings were statistically significant (odds
ratio 1.15, 1.16, and 1.64, respectively). Reaching second-
ary school or college was similarly significantly associated
with increased odds of using the interventions (odds ratio
1.43 and 1.41, respectively), as was having had a previous
pregnancy (odds ratio 1.16) (Table 2). Each additional
ANC visit a woman attended was associated with 2.76Table 2 Logistic regression investigating whether
attendant at home birth is associated with use of
interventions to prevent PPH (N = 63,702)
OR p-value 95% CI
Attendant at delivery
Lay person – – Reference
TBA 1.02 0.896 0.80, 1.29
RDRS trained TBA 2.72 <0.001 2.15, 3.43
Age
15-19 – – Reference
20-24 0.96 0.184 0.90, 1.02
25-29 1.06 0.125 0.98, 1.14
30-34 1.15 0.004 1.05, 1.26
35-39 1.16 0.041 1.01, 1.33
40-44 1.64 0.014 1.11, 2.43
45-49 1.14 0.719 0.56, 2.34
Education
None – – Reference
Primary 1.00 0.943 0.94, 1.05
Secondary 1.43 <0.001 1.36, 1.51
College 1.41 <0.001 1.27, 1.55
Gravidity
1 – – Reference
2+ 1.16 <0.001 1.09, 1.22
Number of ANC visits 2.76 <0.001 2.71, 2.81times the odds of using the interventions (95% confidence
interval, 2.71-2.81).
Discussion
Our primary hypothesis, that having an RDRS trained TBA
present at the delivery would be associated with increased
use of the interventions, was correct. To our knowledge,
this is the first study to examine if type of delivery attendant
is associated with the use of community-based interven-
tions to prevent PPH at home births. Even though all
women who received the CDK also received messages on
how to use the interventions, it seems that having an at-
tendant specifically trained to administer the interventions
significantly increased utilization. Women who had an
RDRS trained TBA present, in comparison to a lay person,
were nearly three times more likely to use misoprostol and
the delivery mat; women with a regular TBA present were
not more likely to use them. A strong explanation for this
association is that the RDRS trained TBA prompted the
use of the interventions during the delivery. This explan-
ation would justify the training of TBAs on these evidence-
based technologies to increase utilization in other low-
resource settings where home births are common and will
continue to be so for many years. The strong association
between number of ANC visits and use of the interventions
shows the potential impact that could come from the in-
creased interaction and message reinforcement by health-
care providers via ANC. In each appointment, the
importance of these interventions and the risk of pregnancy
were reiterated. This could have led women to be more
knowledgeable and more motivated to use misoprostol and
the delivery mat, and repeatedly hearing the instructions
could have made them more confident that they would use
the tools correctly.
Findings related to other covariates demonstrate inter-
esting associations. Increased age was not linearly associ-
ated with increased use of the interventions, but it did
trend in that direction. This finding could be interpreted
in conjunction with the fact that having had a previous
pregnancy was associated with increased use of the inter-
ventions. Younger women who have never been pregnant
and who may not know as much about the dangers and
potential complications of pregnancy may have been less
inclined to utilize these interventions in comparison to
older women, who may have experienced complications
first hand in previous pregnancies, or know other women
who have. An alternative explanation is that these older
women (ages 30–44) might have more autonomy and feel
more empowered to make choices about their healthcare
utilization and delivery practices than younger, nulliparous
women, who may be taking direction from their mothers-
in-law. This potential demonstration of autonomy is likely
why women with secondary and college education are also
more likely to use these interventions in comparison to
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(ages 45–49) lesser utilization of the interventions
(although not statistically significant) could be a result of
having survived several pregnancies by that age and not
being interested in incorporating new, unfamiliar tech-
nologies into their home delivery practices.
A limitation of this study is that all data were self-
reported by the women. Women provided information on
all the covariates during their first antenatal care appoint-
ment with an RDRS CHW, and information on attendant
at delivery and use of the interventions was later self-
reported at a postnatal appointment. Self-reported data
can be less accurate and be subject to social desirability
bias. Direct observation was not possible given the num-
ber of women enrolled in the project, but efforts were
made to collect pill packets from all women after delivery
to assess whether the misoprostol had been used or not.
Despite these efforts, if women falsely reported use of the
interventions (and we do not believe women who did use
the interventions would have any incentive to falsely re-
port non-use), this would result in a differential misclassi-
fication that would bias our results toward the null. Thus
our results would be a conservative estimate of the associ-
ation between attendant at delivery and use of PPH pre-
vention interventions. An additional limitation is that the
data are cross-sectional, thus we cannot make claims of
causality and alternative explanations for the findings
could be made. Women who have an RDRS trained TBA
present at delivery or who attend more ANC could be sys-
tematically different from mothers who had a regular TBA
or lay person present, or who attended fewer ANC visits.
Some unmeasured characteristic (like motivation or
knowledge) could have caused the women to be more
likely to have an RDRS trained TBA present, attend more
ANC appointments, and to use the interventions. Alterna-
tively, both explanations could be true and they could
reinforce each other.
Further evidence is needed to determine the direction of
the relationship between attendant at delivery/number of
ANC visits and use of interventions. As access to miso-
prostol in low-resource settings increases, governments
and non-profits will want to work to increase knowledge
and utilization of this important technology that can re-
duce PPH at home births by as much as 50% [9]. If train-
ing a community-based cohort of TBAs on misoprostol
(and a blood measurement tool) and strengthening re-
cruitment of women for ANC will increase utilization of
these technologies, such efforts could in turn reduce the
impact of maternal morbidity and potentially mortality at-
tributable to PPH in the parts of the world that are most
burdened by this complication. Existing evidence from this
project demonstrates that TBA training on the use of
these interventions can be highly effective [22]. The two
interventions were safely and correctly used at homebirths by the TBAs and data regarding TBA practices and
knowledge indicate adherence to protocol and high know-
ledge retention even 18 months after the training [22].
Despite these positive training results, it is important to al-
ways consider the limitations and risks of utilizing lay
healthcare workers to administer medical interventions.
Trainings should emphasize that providers only use miso-
prostol immediately following delivery (using the recom-
mended dosage after ensuring there is no twin) and that
misoprostol is never to be used for any other purpose.
Side effects, although not addressed in this study, are
an important consideration that program planners and
policymakers should take into account. Health interven-
tions, especially those implemented at home, should al-
ways aim to have as few side effects as possible and the
potential benefits of the intervention should be weighed
against the risk of side effects. In the case of misoprostol
for PPH prevention, the potential reduction in the risk
of PPH is greater than the potential harm of the transi-
ent side effects associated with 600 μg of oral misopros-
tol use; none of the side effects have been associated
with long term morbidity or mortality. Studies have
demonstrated that lower doses of misoprostol are associ-
ated with similar levels of uterine pressure but less ad-
verse effects, which seems to indicate that lower doses
could be used with similar levels of efficacy [25]. A non-
inferiority trial will be required to determine whether
400 μg or 200 μg of misoprostol is as effective as 600 μg
in the prevention of PPH.
Additionally, the quest to conclusively demonstrate
whether prophylactic use of misoprostol reduces mortal-
ity continues. A recent review of existing evidence found
that misoprostol use for the prevention of PPH neither
increased nor decreased the risk of mortality or severe
morbidity. It is important to note that none of the stud-
ies included in this review were individually powered to
detect significant changes in the risk of mortality, but
the findings nonetheless question whether similar pro-
jects to the one presented here would actually reduce
maternal mortality due to PPH [26].
Making evidence-based interventions available is the
first step to improving the safety of home deliveries in
low-resource settings, but the availability of these inter-
ventions alone will not ensure usage. In areas where
complete coverage of SBAs is far from a reality, training
existing TBAs to use these tools can be an effective way to
increase their utilization among women who have these
TBAs present during home delivery, as findings from this
study indicate.
Conclusion
Given misoprostol’s potential to reduce PPH, it is in-
creasingly being made available in low-resource settings
where the majority of PPH occurs. Findings indicate that
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significant impact on utilization of interventions to pre-
vent PPH. PPH prevention efforts targeting home births
that use advanced distribution of misoprostol should thus
consider targeting delivery attendants for intervention-
specific training. Programs that aim to increase the safety
of home deliveries should also perhaps increase efforts to
enroll women in ANC and encourage attendance at mul-
tiple appointments, as ANC attendance was found to be
associated with increased utilization of misoprostol and
the absorbent delivery mat. These efforts, in the context of
a reliable continuum of care, may help to reduce the mor-
bidity and mortality associated with PPH in Bangladesh
and other low-resource countries.
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